Company intelligence / Profile preview

SongGe Biotechnology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Songge Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focused on discovering and developing innovative precision medicines for oncology. The company specializes in the DNA Damage Response (DDR) pathway, leveraging a proprietary drug discovery platform to develop highly selective small molecule inhibitors. Its lead program, SG-2100, is a potent ATR inhibitor currently in Phase 1 clinical trials for patients with advanced solid tumors. Songge aims to exploit synthetic lethality to provide effective therapeutic options for cancers with specific genetic alterations. The company is supported by leading life science investors, including Lilly Asia Ventures and Qiming Venture Partners.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on SongGe Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SongGe Biotechnology.

Explore the full profile